Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)Recruiting
NCT06711887Phase 3Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Lupus Nephritis
United States, Brazil, China, Colombia, Czechia +11 more
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's DiseaseRecruiting
NCT07203001Phase 2Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Still´s Disease
United States, Canada, France, Germany, Italy +3 more
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease PatientsActive Not Recruiting
NCT03814746Phase 3Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Sickle Cell Disease (SCD)
United States, Belgium, Brazil, Canada, Colombia +16 more
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantTerminated
NCT03439046Phase 3Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
Italy
The Mycophenolate Pregnancy RegistryRecruiting
NCT01733082N/AUpdated Jul 10, 2026
Sponsor: Genentech, Inc.
Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases
United States
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple MyelomaActive Not Recruiting
NCT03549442Phase 1Updated Jul 10, 2026
Sponsor: University of Pennsylvania
Multiple Myeloma
United States
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis SuppurativaRecruiting
NCT07489573Phase 4Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
China
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).Recruiting
NCT06751238Phase 1Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Juvenile Psoriatic Arthritis
United States
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisRecruiting
NCT06470048Phase 2Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Diffuse Cutaneous Systemic Sclerosis
United States, Argentina, Austria, Belgium, Brazil +20 more
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine TreatmentCompleted
NCT05631795Phase 4Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Breast Cancer
India
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenRecruiting
NCT07621809Phase 3Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Sjögren´s Disease
United States
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical TrialsActive Not Recruiting
NCT05335876Phase 3Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Spinal Muscular Atrophy (SMA)
United States, Australia, Belgium, Brazil, Canada +14 more
A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.Terminated
NCT05524051Phase 2Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Acute Kidney Injury Following Cardiac Surgery
United States, Argentina, Belgium, Brazil, Canada +10 more
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid TumorsTerminated
NCT03114319Phase 1Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC) · KRAS G12-mutant NSCLC · Esophageal Squamous Cell Cancer (SCC) · Head/Neck SCC
United States, Canada, Italy, Japan, Netherlands +4 more
Dabrafenib and/or Trametinib Rollover StudyRecruiting
NCT03340506Phase 4Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Melanoma · Non Small Cell Lung Cancer · Solid Tumor · Rare Cancers
United States, Argentina, Austria, China, Denmark +7 more
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple MyelomaTerminated
NCT04318327Phase 1Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Multiple Myeloma
United States, Australia, Israel, Singapore
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular LymphomaCompleted
NCT03568461Phase 2Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Follicular Lymphoma
United States, Australia, Austria, Belgium, France +7 more
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung CancersTerminated
NCT06376253Phase 1Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Ovarian Cancer · Lung Cancer
Israel
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AMLActive Not Recruiting
NCT03591510Phase 2Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
FLT3-mutated Acute Myeloid Leukemia
Czechia, Germany, Italy, Japan, Jordan +5 more
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationRecruiting
NCT07441642Phase 2Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Geographic Atrophy Secondary to Age-related Macular Degeneration
United States, Australia, Bulgaria, Canada, Czechia +10 more
A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive SubjectsCompleted
NCT06905327Phase 1Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Mild Hypertension
Australia, New Zealand
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced MalignanciesRecruiting
NCT07340190Phase 1Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Malignancies
Italy, Spain
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Active Not Recruiting
NCT07047118Phase 2Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Cancer, Castration-Resistant
United States, Australia, Austria, Canada, China +10 more
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerActive Not Recruiting
NCT04689828Phase 3Updated Jul 8, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasms
United States, Austria, Belgium, Canada, Czechia +9 more
A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate CancerActive Not Recruiting
NCT07174063Phase 1Updated Jul 8, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Prostate Cancer (mCRPC)
Japan

Previous page Next page